Posts by Amita Sharma, MBBS
-
Pembrolizumab and Nivolumab Not Linked to Increased Mortality in Cancer Patients with Interstitial Lung Disease
Although a thorough risk–benefit analysis is necessary, PD-1 inhibitors should not be uniformly withheld from cancer patients who have underlying interstitial lung disease, according to a study by Sydney B. Montesi, MD, and Amita Sharma, MBBS, clinician-researchers at Massachusetts General Hospital, and colleagues.
